RESULTS
a r t i c l e s
BoNT/A1 is one of the seven major serotypes of BoNT (termed BoNT/ A-G). According to a well-accepted dual-receptor model, the high potency of BoNT/A1 targeting motoneurons is mediated by its receptor-binding domain (H C A), which synergistically binds host protein receptors and gangliosides on the neuronal surface at neuromuscular junctions [1] [2] [3] . The synaptic vesicle glycoprotein 2 (SV2), a family of 12-transmembrane-domain proteins including three isoforms (SV2A, SV2B, and SV2C) in mammals, are protein receptors for BoNT/A1 (refs. 4,5) as well as for BoNT/E 6 , BoNT/D 7 , and potentially BoNT/F 8,9 . We have previously mapped the BoNT/A1-binding site to the fourth luminal domain of SV2 (SV2-L4) 4, 5 . A crystal structure of H C A in complex with the recombinant human SV2C-L4 expressed in Escherichia coli (referred to as bSV2C, with 'b' indicating bacterial expression) has recently been reported 10 . This structure shows that H C A-bSV2C recognition relies mostly on backbone-to-backbone interactions within a small interface (~596 Å 2 ), mediated by two β-strands in H C A and one open edge of the quadrilateral β-helices of bSV2C 10 . This binding mode is in sharp contrast to that of BoNT/B, which recognizes its receptors, synaptotagmin-I and synaptotagmin-II (Syt-I/II), through an extensive side chainmediated protein-protein-interaction network that ensures high binding affinity and specificity toward Syt-I/II 11, 12 . These findings prompt the question of how BoNT/A1 achieves its high efficacy of targeting neurons through receptor recognition based primarily on backbonemediated interactions.
To better understand the molecular mechanism underlying BoNT/ A1's extraordinary neuronal tropism, we determined the crystal structures of H C A in complex with rat bSV2C-L4 and the physiologically more relevant glycosylated human SV2C-L4. We found that BoNT/A1 recognizes two distinct structural elements on SV2C: the protein moiety and an N-linked glycan that is conserved in all known SV2 homologs across vertebrates. Further biophysical, cellular, and functional studies demonstrated that SV2 glycans are essential for BoNT/A1 binding to neurons and for its extreme toxicity at its physiological site of action, the motor nerve terminals. Moreover, we found that the glycanbinding site of BoNT/A1 is also the target of a potent human neutralizing antibody, thus suggesting the potential for SV2 glycan as a new target for the development of BoNT inhibitors. two major differences. First, H C A R1294 forms hydrogen bonds with S519, C520, T521, and D539 of rat bSV2C (Supplementary Fig. 1 ), but these bonds are not present in the structure of the human bSV2C-H C A complex, probably because of the different crystal-packing modes 10 . Interestingly, R1294 exists in only two of the eight BoNT/A subtypes currently known (BoNT/A1 and A4). Second, a cation-π stacking interaction between BoNT/A1 R1156-a residue present exclusively in subtype BoNT/A1-and human SV2C F563, which is thought to be critical for BoNT/A1-SV2C recognition 10 , is not present in the rat bSV2C-H C A complex because rat SV2C has a leucine (L563) in place of human SV2C F563. Leucine is also the homologous residue on SV2A and SV2B in both humans and rodents (Supplementary Note 1). These findings suggest that side chain-mediated interactions may vary substantially among different BoNT/A subtypes and SV2 isoforms and thus are unlikely to provide sufficient binding specificity and affinity between BoNT/A and SV2. Therefore, some crucial BoNT/A-SV2 interactions are missing in the crystal structures of the H C A-bSV2C complexes described here and previously 10 .
SV2 glycosylation is crucial for BoNT/A1 binding to neurons
Native SV2s are glycosylated in neurons 13 , and one of the three Nlinked-glycosylation motifs in L4-which is conserved in all SV2 isoforms across vertebrates-is located at the center of the BoNT/A1binding interface of SV2 (for example, N573 in SV2A, N516 in SV2B, and N559 in SV2C in humans) (Supplementary Note 1). To explore the functional role of this N-linked glycan, we used a molecular replacement approach to express either wild type (WT) SV2A-C or the corresponding deglycosylation mutants (SV2A N573A, SV2B N516A, and SV2C N559A) in hippocampal and cortical neurons cultured from SV2A/SV2B double-knockout (KO) mice. Most hippocampal and cortical neurons do not express SV2C 13 , and thus these neurons cultured from SV2A/SV2B double-KO mice served as an SV2-null neuron model. These deglycosylation mutations of SV2 do not affect protein-protein interactions with BoNT/A1; for example, bSV2C N559A maintains WT-like binding to H C A 10 .
The deglycosylation mutants of SV2A-C all showed lower molecular weights than those of WT SV2s, thus confirming that this asparagine residue is indeed glycosylated in neurons ( Fig. 1a,b and Supplementary Fig. 2) . The expression level of SV2A N573A was comparable to that of WT SV2A, but there was a drastic decrease in SV2B N516A expression and a mild decrease in SV2C N559A expression ( Supplementary Fig. 2) . These results suggest that glycosylation Sv2b a r t i c l e s npg a r t i c l e s at this site is crucial for the folding and/or stability of SV2B and to a lesser degree SV2C, consistently with previously described functions of N-linked glycans 14 .
We thus focused on SV2A N573A and SV2C N559A, and examined SV2-mediated toxin entry for BoNT/A1 and BoNT/D by analyzing the cleavage of synaptosomal-associated protein of 25 kDa (SNAP-25, the substrate of BoNT/A1) and synaptobrevin/vesicle-associated membrane protein 2 (VAMP2, the substrate of BoNT/D) after toxin exposure. BoNT/D served as an internal control for regular trafficking and sorting of SV2 mutants, because BoNT/D uses SV2s as receptors independently of N-glycosylation 7 . Furthermore, we have previously shown that BoNT/B, which does not use SV2 as its receptor, binds and enters WT and SV2-KO neurons to similar extents 4,6 . We found that the SV2-KO neurons did not show BoNT/A1 entry at the conditions tested, probably because of BoNT/A1's low affinity for the ganglioside receptor, which is unable to allow BoNT/A1 cell entry in the absence of SV2 (refs. 15, 16) . Expression of SV2A N573A and SV2C N559A mediated substantially less entry of BoNT/A1 than did the WT SV2s, whereas BoNT/D entry was not affected ( Fig. 1a,b) . These results suggest that SV2 glycosylation at this strictly conserved site contributes to BoNT/A1 binding and entry into neurons.
SV2C glycans greatly enhance H C A binding
Glycosylation is a common and highly diverse post-translational protein modification that profoundly alters protein behavior 14 . Do the N-glycans directly contribute to BoNT/A1 binding? To answer this question, we first carried out surface plasmon resonance (SPR) analysis to examine how H C A binds to human bSV2C. We found that the binding displayed a fast association rate (k a of 1.5 × 10 6 M −1 s −1 ) and a fast dissociation rate (k d of 0.11 s −1 ) (Fig. 1c) , and the overall dissociation constant (K d ) of ~86 nM was comparable to a previously reported K d of 260 nM determined by fluorescence anisotropy 10 . The nature of this transient interaction is consistent with the pattern of backbone-to-backbone interactions revealed in the crystal structure but is difficult to reconcile with the extremely high specificity of BoNT/A1 toward neurons.
We then expressed the human SV2C-L4 (residues V473-T567) as a secreted protein in human embryonic kidney 293 cells (HEK293) to mimic the physiologically relevant glycosylated receptor. HEK293 cells have been widely used to produce glycoproteins with human glycosylation patterns 17 . The resulting protein (referred to as gSV2C, in which 'g' stands for glycosylation) is glycosylated, as evidenced by the appearance of multiple SDS-PAGE bands with masses larger than its peptide mass, comprising heterogeneous glycoforms. We characterized binding of H C A to gSV2C by SPR, which revealed two binding components ( Fig. 1d) . A transient low-affinity binding (K d of ~220 nM) closely resembled the binding of H C A to bSV2C, probably because of heterogeneous glycosylation of SV2C under overexpression conditions 18 . Notably, highaffinity binding (K d of ~15 nM) of gSV2C displayed a ~22-fold slower dissociation rate and an ~4-fold slower association rate than bSV2C. The slightly decreased association rate of gSV2C is likely to stem from restricted carbohydrate flexibility after toxin binding, a physiological event encountered by BoNT/A1 in vivo because the neuronal SV2s are glycosylated. Therefore, the relatively fast association rate displayed by bSV2C artificially increased the binding affinity of bSV2C. Together, these data demonstrate that the glycans of gSV2C stabilize the H C A-gSV2C complex by markedly decreasing the dissociation rate. , and H C A residues that directly interact with the peptide moiety of gSV2C or the N559 glycan are purple and light blue, respectively. gSV2C N559 and the N-linked glycan are labeled as black and red underlined text, respectively. Well-defined water molecules that mediate H C A-glycan binding are shown as green spheres. (e) Extensive interactions between gSV2C N559 glycan and H C A. The plots were generated with LIGPLOT 36 . H C A and gSV2C residues are brown and green, respectively. Hydrogen bonds are indicated by dashed green lines. Key hydrogen-bonding distances are listed in Supplementary Table 1 . Residues involved in hydrophobic interactions are represented by an arc with spokes radiating toward the binding partners that they contact. W1 to W10 correspond to the following waters in PDB 5JLV: A1545, A1484, C712, A1476, C711, A1475, A1445, C729, A1485, and C701.
a r t i c l e s
The crystal structure of H C A in complex with human gSV2C
We next determined the crystal structure of H C A in complex with human gSV2C at 2.0-Å resolution ( Table 1 ). The overall architecture of the H C A-gSV2C complex is similar to that of the bSV2C complex (r.m.s. deviation of ~0.88 Å over 489 aligned Cα pairs). We observed a complex-type N-linked glycan attached to gSV2C N559, with clear electron densities for the quadruple-saccharide core made up of two N-acetylglucosamines (NAGs), a mannose (BMA), and a fucose (FUC) ( Fig. 2 and Supplementary Fig. 3 ). Two other putative N-linked-glycosylation sites (N484 and N534) are localized on SV2C-L4 and also conserved on SV2A and SV2B (Supplementary Note 1) . We observed only one NAG resolved in the electron density for the N534 glycan, probably because of its high mobility, whereas we identified no sugar at N484. SV2C N484 and N534 are located far away from BoNT/A1-binding interface and thus are unlikely to directly participate in toxin binding. Remarkably, the N559 glycan directly interacts with H C A through a network of hydrogen bonds and van der Waals contacts. The most prominent interactions are stacking interactions between residues F953 and H1064 of H C A and the hydrophobic faces of the two NAGs. In addition, ten well-defined water molecules act as molecular 'glue' in the glycan-H C A interface, thus further strengthening the interactions (Fig. 2d,e and Supplementary Table 1 ). These interactions almost double the contact area between H C A and SV2C from 557 Å 2 to 925 Å 2 . There are also weak electron densities beyond the mannose, thus suggesting that there might be more extensive H C A-glycan interactions that were not resolved, possibly because of the inherent flexibility of glycans and heterogeneous glycosylation. This structure unambiguously reveals that the N559 glycan of SV2C is recognized directly by BoNT/A1 as an integral part of the toxin-binding site.
SV2 glycan is critical for BoNT/A1 binding to neurons
We then sought to understand the functional role of protein-glycan interactions in BoNT/A1-SV2 recognition. On the basis of the crystal structure, we designed a set of single-site mutations on H C A that selectively disrupt glycan binding: F953G and H1064G abolish the critical stacking of aromatic side chains against the sugar rings, and F953R, H1064R, G1292Q, and G1292R cause clashes between their bulky side chains and the N559 glycan. None of these mutations affected H C A folding and stability, as verified by thermal denaturation experiments, nor did they affect H C A binding to bSV2C, as demonstrated by pulldown and SPR studies. As expected, these mutants markedly decreased H C A binding to gSV2C, a result strongly supporting the direct involvement of the N559 glycan of SV2C in BoNT/A1 binding ( Supplementary Figs. 4 and 5a-c) . Interestingly, SPR studies showed that the glycan-binding-deficient H C A F953G bound much more weakly to gSV2C than to bSV2C (K d values of ~760 nM and ~160 nM, respectively) ( Supplementary Fig. 5d,e) . Therefore, the native neuronal SV2s that are always glycosylated initially impose steric hindrances in BoNT/A1 recognition. However BoNT/A1 overcomes this obstacle by directly using SV2 glycans to strengthen binding.
We examined how these H C A mutants bind to native SV2s in neurons. First, we analyzed binding of H C A to endogenous SV2A and SV2B by using cultured rat hippocampal and cortical neurons 13 (Fig. 3a,b) . The mutations F953G, F953R, G1292Q, and G1292R largely abolished binding of H C A to neurons; H1064G and H1064R also drastically decreased binding, thus suggesting that protein-glycan interactions are essential for BoNT/A1 binding to native SV2s on neurons. We further examined neurons that exclusively expressed SV2A, SV2B, or SV2C: hippocampal and cortical neurons cultured from Sv2a +/ + Sv2b −/− mice served as neurons that express only SV2A, and we created neurons that expressed only SV2B or SV2C by infecting neurons cultured from Sv2a −/− Sv2b −/− mice with lentiviruses for expression of SV2B or SV2C, respectively. Mutating glycan-binding residues on H C A (for example, F953G, G1292R, and H1064G) decreased H C A binding in all cases tested, thus demonstrating that BoNT/A1-glycan interactions are conserved and are essential for all three SV2 isoforms (Fig. 3c-e and Supplementary Fig. 6 ).
SV2 glycan allows tolerance to genetic changes in BoNT/A
Complementing our studies on protein-glycan interactions, we also examined the contribution of side chain-mediated protein-protein a r t i c l e s interactions to SV2 recognition, which varied substantially among the eight different BoNT/A subtypes (Supplementary Note 2) . In this regard, we mutated residues R1156 and R1294 of BoNT/A1 to their counterparts in other BoNT/A subtypes (for example, R1156E and R1294S), thereby disrupting their interactions with the peptide moiety of SV2C without affecting glycan binding. We used the double mutant H C A T1145A T1146A as a control 10 . These two threonine residues, located at the core of the protein-protein interface, are conserved in all BoNT/A subtypes (Supplementary Note 2) . We found that binding of H C A T1145A T1146A to cultured rat hippocampal and cortical neurons was abolished (Fig. 3a,b) . This result was consistent with the results of an earlier study showing that H C A T1145A T1146A cannot bind to bSV2C 10 . Interestingly, we found that H C A R1156E and R1294S still bound substantially to neurons (Fig. 3a,b) , despite showing decreased binding to both human bSV2C and gSV2C in vitro (Supplementary Fig. 5a-c) . These data suggest that loss of side chain-mediated interactions at R1156 and R1294 of BoNT/A1 is tolerated on neuronal surfaces, probably because of the presence of SV2 glycan and co-receptor gangliosides.
Glycan binding is essential for BoNT/A1's high potency
To further establish the physiological relevance of protein-glycan interactions, we produced full-length BoNT/A1 containing singlesite glycan-binding-deficient mutations (F953G, F953R, H1064G, H1064R, G1292V, or G1292R) and examined their neurotoxicity at motor nerve terminals by using ex vivo mouse phrenic nerve hemidiaphragm (MPN) assays 19 (Fig. 3f) . Remarkably, all of these mutations drastically decreased the potency of BoNT/A1. BoNT/A1 F953R had no detectable toxicity even at the maximal concentration tested (200 nM), thus it displayed a >10 6 -fold reduction of neurotoxicity despite showing fully functional Zn 2+ endoprotease activity in vitro.
The mutation G1292R also severely decreased the toxicity, by 350fold (ref. 20) . Mutations H1064G and H1064R displayed three-and seven-fold decreases, respectively. These data demonstrate that glycan binding is essential for the high potency of BoNT/A1 at the motor nerve terminals, its physiological site of action.
The SV2 glycan-binding mode is conserved in BoNT/HA We next examined whether glycan binding is conserved in natural variants of BoNT/A1, because BoNT genes have actively evolved, and at least 40 different subtypes of BoNT have been reported 21 . In this regard, we focused on a newly reported mosaic toxin type HA (BoNT/ HA, also known as BoNT/FA), which has a hybrid-like structure including a BoNT/A1-like H C [22] [23] [24] [25] [26] . H C HA is highly similar to H C A (~83% identical amino acids) (Supplementary Note 2) . Sequence alignment revealed that most of the glycan-binding residues, such as F953 and H1064, are conserved in H C A and H C HA, but residues R1156 and R1294 of H C A are M1148 and S1286 in H C HA. H C HA showed much weaker binding than H C A to human bSV2C, whereas its binding to human gSV2C was comparable to that of H C A (Fig. 4a) . These results suggest that the loss of side chain interactions due to genetic changes of M1148 and S1286 in H C HA is compensated by SV2C glycan. In contrast, H C HA F943G (equivalent to H C A F953G) did not bind to gSV2C in a pulldown assay, nor did it bind to cortical neurons, probably because of the disruption of glycan binding (Fig. 4a,b) . These data confirm that a similar glycan-binding mode is conserved in H C HA and is critical for its binding to SV2s on neurons.
Furthermore, we found that the SV2 glycan-binding residues are largely conserved in seven of the eight BoNT/A subtypes (BoNT/A1-A3 and A5-A8) identified to date 27 (Supplementary Note 2) . Notably, BoNT/A4 is the only one with an arginine residue (R1292) at the equivalent position of BoNT/A1 G1292. Because the BoNT/A1 G1292R mutant drastically decreases BoNT/A1 toxicity by blocking its binding to SV2 glycan 20 ( Fig. 3 and Supplementary Figs. 5 and 6) , we suggest that the disrupted glycan binding caused by residue R1292 is a major reason for the ~1,000-fold reduced biological activity of BoNT/A4 compared with that of BoNT/A1 (ref. 28 ). Together, our findings suggest that BoNT/A1 and variants use the genetically invariable carbohydrates as surrogate amino acids to engage the host receptors. Synergistic binding to two distinct cell-surface receptors, SV2 (including its peptide and glycan moieties) and ganglioside, provides a plausible explanation for the high potency of BoNT/A and its remarkable specificity for nerve terminals (Fig. 4c) . The new glycan receptor for BoNT/A presents a promising target for developing therapeutic toxin inhibitors. Remarkably, we found that a BoNT/A1-neutralizing human monoclonal antibody family, CR2/ CR1, which is currently in clinical trials 29, 30 , directly targets the glycan-binding site on H C A, such that the first antigen-binding loop of the light-chain variable region occupies the glycan-binding site (Fig. 5a) .
The key epitopes for CR2/CR1 include residues F953 and H1064 (ref. 29) . Interestingly, residue F36 of CR2/CR1 uses a π-stacking interaction to bind BoNT/A1 H1064, mimicking its interactions with SV2C N559 glycan. CR2/CR1 also blocks binding of BoNT/A1 to bSV2C 20 , but this effect is due to the large size of CR2/CR1 causing a side-to-side clash with bSV2C, because CR2/CR1 and bSV2C have nonoverlapping binding sites on H C A ( Fig. 5b-d) . Together our data reveal that the strong neutralization potency of CR2/CR1 is empowered by simultaneously blocking BoNT/A1 binding to the glycan and peptide moieties of SV2.
DISCUSSION
Host cell-surface glycans are crucial for pathogen recognition. For example, the host range (e.g., swine, avian or human) of influenza hemagglutinins is largely dependent on carbohydrates 31 . Our results reveal a new host-recognition strategy by which pathogens simultaneously recognize a protein segment and the neighboring glycans as a composite binding site. This unique strategy uses a conserved post-translational modification as an evolutionarily static recognition site, in addition to protein-protein interactions that encode the location and specificity information. Together, this strategy provides a powerful solution to address the competing needs of achieving highly specific binding while also tolerating residue changes in receptors across multiple isoforms and species variants. Intriguingly, a similar strategy may be used by some important broadly neutralizing human antibodies, which are capable of neutralizing multiple serotypes of targeted viruses, such as dengue viruses and HIV-1, by simultaneously recognizing the protein components and the highly conserved glycans on virus proteins [32] [33] [34] . A similar model has also recently been demonstrated for Notch1 receptor binding with its ligand Delta like 4 (DLL4) 35 , such that DLL4 binds to the fucose and glucose at the base of an O-glycosylation site located within the protein-protein interface. Therefore, our findings offer a promising strategy for engineering ligand-receptor interactions and broadly neutralizing antibodies for therapeutic applications.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Coordinates and structure factors for the H C A-bSV2C and H C A-gSV2C complexes have been deposited in the Protein Data Bank under accession codes PDB 5JMC and PDB 5JLV, respectively.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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